CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 217 enrolled
Drug / intervention
Atorvastatin +4 moredrug
Likely dose
Atorvastatin 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00715273
NCT00715273Phase 4Completed
CompareCT.gov

Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy

University of Washington·interventional·Posted Jul 15, 2008·Updated Jun 7, 2022

In Brief

A Phase 4 clinical trial evaluating Atorvastatin, Niacin, and 3 other interventions for Coronary Artery Disease and 2 related conditions. Completed, enrolled 217 participants across 4 sites.

Detailed Summary

Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. This study will examine the effectiveness of a combination of cholesterol-lowering medications at decreasing the fat content of atherosclerotic deposits in people who have coronary artery disease or carotid artery disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Pfizer, Abbott, Daiichi Sankyo, Upsher-Smith Laboratories

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 15, 2008
Enrollment StartMay 1, 2001
Primary CompletionDec 12, 2018
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 17.6 yearsPosted 18.0 years ago

Interventions

Atorvastatindrug

10 to 80 mg of atorvastatin each day

Niacindrug

2000 mg of niacin each day

Colesevelamdrug

3.8 g of colesevelam each day

Placebo Niacindrug

Placebo niacin each day

Placebo Colesevelamdrug

Placebo colesevelam each day